Table 3.

Adverse Outcomes

Adverse OutcomeTotal Study Population (n = 40)Patients With Chorioamnionitis
(n = 22)
Treatment (n = 20)Placebo (n = 20)Treatment (n = 14)Placebo (n = 8)
Died before discharge3 (15%)3 (15%)3 (21%)2 (25%)
Sepsis5 (25%)6 (30%)3 (21%)4 (50%)
Patent ductus arteriosus (treated)8 (40%)13 (65%)5 (36%)4 (50%)
Necrotizing enterocolitis2 (10%)2 (10%)2 (14%)2 (25%)
Gastrointestinal perforation1 (5%)1 (5%)00
Intraventricular hemorrhage
 Grades I and II5 (25%)7 (35%)2 (14%)4 (50%)
 Grades III and IV2 (10%)1 (5%)2 (14%)0
Retinopathy of prematurity (percentage of survivors)
 Stages 1 and 212 (71%)8 (47%)8 (67%)3 (50%)
 Stage 34 (24%)6 (35%)3 (21%)3 (50%)
 Laser therapy1 (6%)4 (24%)1 (13%)2 (33%)